Acute pharyngitis

disease

On this page

Also known as pharyngitis, acute

Summary

Acute pharyngitis (MONDO:0020600) is a disease with 4 GWAS associations across 17 studies and 8 clinical trials. Top therapeutic interventions include esflurbiprofen, flurbiprofen, and menotropins. A subtype of pharyngitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

GWAS associations: 4
Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acute pharyngitis
Mondo ID	MONDO:0020600
EFO	EFO:0009657
ICD-10-CM	J02
ICD-11	1791890273
NCIT	C34355
SNOMED CT	363746003
UMLS	C0001344
MedGen	114
Is cancer (heuristic)	no

Also known as: acute pharyngitis · pharyngitis, acute

Data availability: 4 GWAS associations (17 studies).

Disease family

This is a subtype of pharyngitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › upper respiratory tract disorder › pharyngitis › acute pharyngitis

Related subtypes (1): streptococcal sore throat

Genetics & variants

GWAS landscape

4 GWAS associations across 17 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs142229199	8e-09	MIR3144 - RNU6-214P	?
chr2:70901383	3e-08		T	2.09
chr3:115056115	3e-08		C	0.07
chr7:154200894	5e-08		C	2.76

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90473640	UK Biobank Whole-Genome Sequencing Consortium	2025	22,222	436,218	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90667848	UK Biobank Whole-Genome Sequencing Consortium	2025	22,222	436,218	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90478079	Verma A	2024	14,147	401,754	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90080087	Backman JD	2021	10,891	351,064	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084073	Backman JD	2021	10,891	351,064	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90080086	Backman JD	2021	6,744	365,218	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084072	Backman JD	2021	6,744	365,218	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90478078	Verma A	2024	6,152	102,654	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481102	Verma A	2024	6,152	102,654	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90726940	Kim HI	2026	4,822	39,204	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	4

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	4

Functional consequences

Consequence	Count
unknown	3
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	Consequence	Gene	p-value	Tier
rs142229199	6	120245192	G>A	intergenic_variant	MIR3144 - RNU6-214P	8e-09	Tier 4: intronic/intergenic
chr2:70901383						3e-08	Tier 4: intronic/intergenic
chr3:115056115						3e-08	Tier 4: intronic/intergenic
chr7:154200894						5e-08	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE2	2
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01986361	PHASE3	COMPLETED	Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method
NCT04027322	PHASE2/PHASE3	COMPLETED	Inhaled Steroids for Acute Pharyngitis.
NCT06932328	PHASE2	RECRUITING	Qinqiao Yan Shu Granules for the Treatment of Acute Pharyngitis (Exterior Wind-Heat Syndrome) Phase II Clinical Trial
NCT04470089	PHASE2	TERMINATED	A Clinical Trial Investigating the Short-term Relief of Symptoms of Acute Pharyngitis by Treatment With Three Different Doses of MYRAMISTIN™ Oromucosal Spray
NCT07569939	Not specified	NOT_YET_RECRUITING	Evaluation of Treatments for Sore Throat Associated With Acute Pharyngitis and/or Viral Tonsillitis
NCT01720927	Not specified	COMPLETED	Pakistan Epidemiological Survey in Acute Pharyngitis
NCT02160912	Not specified	COMPLETED	Non Interventional Study (NIS) Regarding the Application of Ectoin Mund- & Rachenspray in Patients With Acute Laryngitis and/or Acute Pharyngitis
NCT04203810	Not specified	COMPLETED	Effectiveness and Tolerability of Ectoin® Mouth and Throat Spray Althaea Honey (ERS09)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ESFLURBIPROFEN	4	1
FLURBIPROFEN	4	1
MENOTROPINS	4	1
SODIUM CHLORIDE	4	1
MIRAMISTIN	2	1

Drugs: Esflurbiprofen, Flurbiprofen, Menotropins, Sodium Chloride